Bing

SEARCH HISTORY

The average gain from the low of the summer to the high has been 9.2% since 1964, says The Stock Traders Almanac. Summer is the poorest performing season by this measure. Lately, summer has been just as unpredictable – cementing its shaky …
USA TODAY MONEY · ByMatt Krantz · 6/18/2015
Since Biogen reported preliminary findings from the BIIB037 trial in December, the stock had gained 41 percent. Investors have awaited the full trial results to gauge whether they back up the initial optimism over the drug’s chances. Chief Executive ...
Bloomberg · ByMakiko Kitamura · 3/20/2015
I don’t believe biotech is in a bubble; on the contrary, I am recommending that you reenter the sector via this recommended exchange-traded fund, explains Nicholas Vardy, editor of Bull Market Alert. We are buying ProShares Ultra Nasdaq Biotechnology …
The Money Show · 4/15/2015
Jeff Cooper, author of the Daily Market Report made several calls today. Hi initiated a long swing on Agnico Eagles Mines (AEM), believing that that a major low for gold would be in no later than the end of July. He also initiated a short on Skyworks ...
Minyanville · 7/24/2015
The fastest-growing segment of the global population is aged 60 and over ... That compares with an average 7% return for the MSCI World NR stock index. For more non-U.S. exposure, consider the iShares Global Healthcare ETF, which charges 0.48% for …
Time · 8/5/2014
The $8.8 billion IBB allocates 37.8% of its combined weight to biotech giants Gilead (NasdaqGS: GILD), Amgen (NasdaqGS: AMGN), Regeneron (NasdaqGS: REGN), Biogen (NasdaqGS: BIIB) and Celgene (NasdaqGS: CELG). The $2.4 billion XBI features …
ETF Trends Setting The Pace · 6/9/2015
You may be bored, or stuck at a dead end job in academia, Big Biotech, or Big Pharma. You are intrigued by a job posting you just saw at a biotech startup, and the company appears to be showing some interest in you. It’s a great position to be in ...
Xconomy · ByLuke Timmerman · 9/16/2013
Today, Evercore ISI analyst Mark Schoenebaum trumpeted his belief that Axovant ($AXON ... a $60 share price--unless the Phase III for the one-trick pony fails and the stock drops to $2 a share. Schoenebaum, who traded in his independent online spotlight ...
Fierce Biotech · ByJohn Carroll · 7/6/2015
The multiple sclerosis market is increasingly moving away from injectable treatments in favour of pills such as Novartis' Gilenya and Biogen Idec's < BIIB.O> Tecfidera. But Genzyme hopes Lemtrada's ability to reduce the risk of relapse of the disease will ...
Reuters · 11/15/2014
Google Inc (NASDAQ:GOOGL)’s stock on 07 July traded at beginning with a price of $547.43 and when day-trade ended the stock finally advanced 0.81% to end at $550.03. Google Inc (NASDAQ:GOOGL)’s showed weekly performance of 1.62%.
benchmarkmonitor.com · 7/8/2015

Biogen Idec

Company
Biogen is a global biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and deliver…
Biogen is a global biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.
Data from: Wikipedia · Freebase